BIOGEN INC. reported revenue of $2.74B for the period ended 2026-06-30, +3.4% year on year. Net income was $0.10B, a 3.6% net margin on a 71.6% gross margin. The largest revenue line is Multiple sclerosis (MS) product revenue (1) at 35% of the total. Free cash flow for the period was $0.31B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $2.74B | +3.4% |
| Gross profit | $1.96B | — |
| Operating income | $0.48B | — |
| Net income | $0.10B | -84.6% |
| Gross margin | 71.6% | Net margin 3.6% |
| Revenue Q/Q | +10.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| Multiple sclerosis (MS) product revenue (1) | $0.96B | 35.2% |
| Rare disease revenue (2) | $0.60B | 22.0% |
| Revenue from anti-CD20 therapeutic programs | $0.51B | 18.8% |
| Contract manufacturing, royalty and other revenue | $0.24B | 8.8% |
| Biosimilars revenue | $0.15B | 5.6% |
| Specialized immunology revenue (3) | $0.13B | 4.7% |
| Other product revenue (4) | $0.07B | 2.6% |
| Alzheimer's collaboration revenue (5) | $0.06B | 2.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.78B | 28.4% |
| R&D | $0.53B | 19.4% |
| SG&A | $0.71B | 25.9% |
| Tax & other | $0.39B | 14.1% |
| Item | Amount |
|---|---|
| Total assets | $32.09B |
| Total liabilities | $13.24B |
| Shareholders' equity | $18.85B |
| Equity / assets | 58.7% |
| Operating cash flow | $0.45B |
| Capital expenditure | $0.14B |
| Free cash flow | $0.31B |
| Cash conversion (OCF / net income) | 460% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
BLK ・ BX ・ XYZ ・ BNY ・ BA ・ BKNG ・ BSX ・ BMY ・ AVGO ・ BR ・ BRO ・ BF.B
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies